CA-QUANTA-CLOUD
15.3.2021 16:02:08 CET | Business Wire | Press release
Quanta Cloud Technology (QCT), a global data center solution provider, announced its growing portfolio of Total Cloud Solutions featuring AMD EPYC™ 7003 Series Processors . QCT systems supporting AMD EPYC™ 7003 series processors help their customers adapt to changing business needs, while offering incredible performance with faster time to results.
Among QCT’s Total Cloud Solutions making their debut is the all-new QuantaGrid D43N-3U server which supports the 3rd Gen AMD EPYC™ processors and provides the highest CPU-GPU ratio in the market.
AMD EPYC™ 7003 Series Processors
Based on the “Zen 3” core architecture, the AMD EPYC™ 7003 Series processors drive a new standard for the modern data center with fantastic performance capabilities. Designed to be the world’s highest performance x86 server processor, it helps companies maximize their investments while providing an attractive data center ROI. AMD also continues to drive x86 security innovation with a group of advanced security features and a silicon embedded security subsystem that helps protect a customer’s most valuable asset – their data.
“We designed the EPYC™ 7003 Series processors to give our customers exactly what they said they needed, performance across all workloads and the ability to drive more time to value, right out of the box,” said Ram Peddibhotla, corporate vice president, EPYC product management, AMD. “With leadership architecture, performance, and modern security features, EPYC™ 7003 Series processors are a superior choice and continue to drive the standard for the modern data center.”
QCT QuantaGrid D43N-3U server
The D43N-3U is a dual-socket server designed to support up to 4 double-width or 8 single-width GPU accelerators without any PCIe switch chips. Not only does this reduce the latency between GPU and CPU, but it allows the system to act as a powerhouse for various disciplines - i.e. HPC, weather forecasting, automotive, AI training and inference, graphic rendering, cloud gaming, etc.
“QCT is always looking to deliver products that meet changing workload needs,” said Mike Yang, President of QCT. “With the QuantaGrid D43N-3U, we worked with our strategic partner, AMD, to deliver innovations that combine all the advantages of the 3rd Gen AMD EPYC processors with our comprehensive designs to allow our customers to arm their data center with the resources to drive performance in a consolidated solution.”
QCT is tapping the full functionality of the AMD EPYC™ 7003 Series processors with more compute, more memory, more expansion possibilities, and more bandwidth between nodes to enable businesses with access to more data resulting in faster answers. Organizations of all sizes can benefit from the innovation and performance breakthroughs EPYC™ 7003 Series processors deliver. QCT also offers other QuantaGrid models that support AMD EPYC™ processors for HPC and more.
For more details visit https://go.qct.io/EPYC .
About Quanta Cloud Technology (QCT)
QCT is a global data center solution provider that combines the efficiency of hyperscale hardware with infrastructure software from a diversity of industry leaders to solve next-generation data center design and operational challenges. QCT serves cloud service providers, telecoms and enterprises running public, hybrid and private clouds.
Product lines include hyperconverged and software-defined data center solutions as well as servers, storage, switches and integrated racks with an ecosystem of hardware components and software partners. QCT designs, manufactures, integrates and services its offerings via its own global network. The parent of QCT is Quanta Computer, Inc., a Fortune Global 500 corporation. www.QCT.io
AMD, the AMD arrow logo, EPYC, and combinations thereof are trademarks of Advanced Micro Devices, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210315005004/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom